A Clinical Trial Using Attrition Combined with 5-Aminolevulinic Acids Based Photodynamic Therapy in Treating Squamous Cell Carcinoma.
BACKGROUND Squamous cell carcinoma (SCC) is the second most common type of skin cancer, for which non- or mini-invasive treatment is of critical importance. 5-aminolevulinic acids based photodynamic therapy (ALA-PDT) is a mini-invasive approach that causes focal tumor cell injury, apoptosis, and necrosis through light sensitivity. The efficacy of combining ALA-PDT and surgery in treating SCC, however, has not been demonstrated. MATERIAL AND METHODS A total of 60 SCC patients were randomly assigned into attrition plus ALA-PDT group (experimental group) and single ALA-PDT treatment group (control group). Clinical efficacy, recurrence rate, and adverse effects were analyzed in conjunction with H&E staining and immunohistochemistry (IHC) staining for p53 expression. RESULTS The overall effective rate of the experimental group was 73.3%, which was significantly higher than that of the control group (46.7%). The experimental group also had a lower recurrence rate (16.6% versus 30.0%, p<0.05). Similar rates of adverse effects existed between the two groups. After treatment, abnormal cells disappeared, while the p53 positive rate after treatment was elevated in the two groups (p<0.05 comparison of before and after treatment). The experimental group had a higher p53 positive rate compared to the control group (p<0.05). CONCLUSIONS Combined therapy of attrition with ALA-PDT significantly elevated the effective treatment rate and can decrease the recurrence rate with reliable safety in treating SCC, thus ALA-PDT can be used as an optimal plan for SCC treatment.
Department of Dermatology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China (mainland).
Jianzhong
J
Peng
Department of Dermatology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China (mainland).
Weiguo
W
Feng
Department of Dermatology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China (mainland).
Xianyan
X
Luo
Department of Dermatology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China (mainland).
Tao
T
Wang
Department of Dermatology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China (mainland).
Wenzhong
W
Xiang
Department of Dermatology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China (mainland).
Yeqin
Y
Dai
Department of Urology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China (mainland).
Jingyu
J
Zhu
Department of Dermatology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China (mainland).
Junhui
J
Zheng
D000368:Aged; D000622:Aminolevulinic Acid / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000473:pathology; D010778:Photochemotherapy / Q000009:adverse effects / Q000379:methods*; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D016896:Treatment Outcome
D017319:Photosensitizing Agents; D000622:Aminolevulinic Acid